RECKGIST score effectively predicts recurrence in neurofibromatosis type 1-associated GISTs, especially for tumors under 30 mm. Larger GISTs (over 30 mm) have a higher risk of metastasis, with ...

Women with early-stage hormone receptor (HR)-positive breast cancer who had low to intermediate scores on the Oncotype DX Breast Recurrence Score assay did just as well on neoadjuvant endocrine ...

Please provide your email address to receive an email when new articles are posted on . Further study is needed to identify potential drivers of the association Low household income appeared ...

MADISON, Wis., April 28, 2022 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leader in advanced cancer diagnostics, today announced that recommended use of its Oncotype DX Breast Recurrence ...

Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non–Small Cell Lung Cancer RNA sequencing was performed on 647 previously untreated stage I-III estrogen receptor–positive/human ...

A retrospective study validates the Oncotype 21-gene breast recurrence score as a predictive biomarker of adjuvant chemotherapy benefit in women with estrogen receptor (ER)-positive/human epidermal ...

Overall, 597 of 630 patients were analyzable—247 patients had stage II, and 350 had stage III colon cancer. The continuous Recurrence Score was significantly associated with RFI after adjustment for ...

Please provide your email address to receive an email when new articles are posted on . SAN ANTONIO — Outcomes among women with breast cancer who have similar 21-gene recurrence scores may vary by ...

"We have known that income level is associated with incidence of poor-prognosis triple-negative breast cancer, but our new study presents the first data to show that income level impacts survival even ...

A new risk score can help predict whether a pancreatic cancer survivor will suffer a recurrence of cancer The 13-point risk score can help doctors more closely monitor patients at higher risk About 10 ...

The recurrence score based on the 21-gene breast-cancer assay has been clinically useful in predicting a chemotherapy benefit in hormone-receptor–positive, human epidermal growth factor receptor 2 ...